Recently, infusion using in vitro-generated donor T cells reactive against peptides derived from CML-associated antigens was reported in a trial with 14 patients with CML, who received conditioning therapy followed by CD34+ selected HSCT from matched siblings or unrelated donors. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.